Horsholm, Denmark, October 1, 2015 / B3C newswire / -- ExpreS2ion Biotechnologies , a private Danish company, (“ExpreS2ion”) announced today the execution with Boston Children’s Hospital (“Boston Children’s”), located in Boston, Massachusetts, USA, of a non-exclusive research license agreement to use ExpreS2ion’s proprietary recombinant protein expression platform ExpreS2 for Boston Children’s academic research. Boston Children’s is the pediatric teaching affiliate of Harvard Medical School.
The ExpreS2 platform is being used by top academic and top private industry teams to solve protein expression challenges. The system has proven to be instrumental in advancing research in neglected diseases, including malaria research and vaccine projects, where other expression systems have failed to yield the native properties of the parasite proteins – or even failed to express the proteins. ExpreS2 provides high quality, very homogenous expressed proteins, qualities that are needed in structural biology studies.
“ExpreS2ion aims to support the development of novel drugs through solving protein production challenges. Our proprietary technology platform can deliver protein for laboratory use and is also compatible with current Good Manufacturing Practice (cGMP). This interaction with Boston Children’s is part of our strategy to support top academic teams in protein expression. It is our hope that this license will advance the understanding of relevant immunological processes and of malaria vaccine candidates.” said Wian de Jongh, Ph. D., Chief Scientific Officer, ExpreS2ion.
About ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies is a world leading CRO specializing in developing cell lines and processes based on Drosophila S2 cells. Our company has a proprietary and complete S2 recombinant protein expression platform: ExpreS2, which was developed over more than ten years. ExpreS2 is a uniquely successful tool for non-viral insect-cell based expression, and we are the only company with in-depth practical experience in how to use it – both in preclinical development and in clinical trials. The ExpreS2 platform is excellent in all phases of drug discovery, R&D and manufacturing as it offers fast access to protein and easy establishment of stable polyclonal pools. This results in high protein-expression levels with a regulatory friendly expression system.
Contact
ExpreS2ion Biotechnologies ApS.,
Sancha Salgueiro
+45-41666121
sas@expres2ionbio.com
http://www.expres2ionbio.com
SCION Science Park
Agern Alle 1
2970 Horsholm, Denmark
Help employers find you! Check out all the jobs and post your resume.
